LymphomaMantle-Cell Lymphoma

Stem-Cell Transplantation in Mantle-Cell Lymphoma

Although stem-cell transplantation can be an effective treatment for mantle-cell lymphoma, patients have many things to consider when deciding whether this option is appropriate for them.
MCL Monthly Minutes

The choice of treatment for mantle-cell lymphoma depends on several factors, including the stage of disease, the age of the patient, and the patient’s overall health. Overall health is important, because some patients require more gentler treatments than others.1,2

High-dose chemotherapy is often used to kill cancerous white blood cells in patients with lymphoma (including mantle-cell lymphoma). Unfortunately, chemotherapy also kills some of the stem cells the body needs to replace the cancerous cells with new, healthy cells. A stem-cell transplant replaces the stem cells that were destroyed and restores the ability of the bone marrow to make new blood cells.1,3

Because the combination of high-dose chemotherapy and stem-cell transplant places great strain on the body, this approach may not be an option for every patient. Fit patients are usually better able to tolerate the treatment, which may keep mantle-cell lymphoma under control for a longer period of time.1,4 Patients and their loved ones have many factors to consider when deciding whether a stem-cell transplant is an appropriate treatment for them.

In mantle-cell lymphoma, eligible patients receive an autologous stem-cell transplant, which means their own blood-forming stem cells are collected. The collection process, during which blood is drawn from a vein, may take from 1 to 5 days. The blood is then put through an apheresis machine, which separates the stem cells from the other blood cells.3

Autologous stem-cell transplantation is most commonly recommended when patients have aggressive mantle-cell lymphoma that responds to chemotherapy. The treatment usually requires a hospital stay with a long recovery process, which comes with a number of side effects. Although most of these side effects are temporary—such as low blood cell counts, infection, fatigue, and hair loss—stem-cell transplants may also result in infertility.3

It is important for patients to discuss all possible therapeutic options—including their risks and possible side effects—with their healthcare team to determine whether a stem-cell transplant is the right option.


  1. Lymphoma Research Foundation. Understanding the Stem Cell Transplantation Process. July 2016. Accessed May 19, 2019.
  2. Lymphoma Action. Mantle cell lymphoma. Accessed May 19, 2019.
  3. Memorial Sloan Kettering Cancer Center. Autologous Stem Cell Transplant: A Guide for Patients & Caregivers. Accessed May 19, 2019.
  4. Helwick C. Mantle cell lymphoma: Is transplantation still necessary? The ASCO Post. September 25, 2015. Accessed May 19, 2019.
Recommended For You
Yescarta Leads to Long-Term Responses in Patients with Advanced Follicular Lymphoma or Marginal-Zone Lymphoma
By Wayne Kuznar
A total of 80% of patients with relapsed (coming back) or refractory (not responding to therapy) slow-growing (indolent) non-Hodgkin lymphoma (NHL)—including patients with follicular lymphoma or marginal-zone lymphoma (MZL)—achieved a complete response (no sign of cancer) to Yescarta (axicabtagene ciloleucel), an anti-CD19 CAR T-cell therapy.
Keytruda New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
By Phoebe Starr
Treatment with the PD-1 inhibitor Keytruda (permbrolizumab) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with Adcetris (brentuximab vedotin), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Keytruda Immunotherapy Prolongs Survival in Patients with Relapsed or Refractory Hodgkin Lymphoma
By Phoebe Starr
Using the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, prolongs the time without disease progression in patients with relapsed (coming back) or refractory (not responding to treatment) classical Hodgkin lymphoma compared with the current standard of therapy of Adcetris (brentuximab vedotin), an antibody–drug conjugate.
CONQUER CamLymphomaPatient Stories
CONQUER Cam: A Spotlight on Brad Power
By Brad Power
Bradford Power took the credibility he had as a patient diagnosed with cancer and used it to fuel his purpose and mission of helping others navigate their cancer diagnosis and treatment.
Last modified: June 14, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.